Key Points
- The UK Government’s Sovereign AI venture fund has backed British startup Potential Sciences through an eight-figure funding round announced on 5 November 2026.
- The investment aims to support the company’s development of artificial intelligence technology for chemical design and drug discovery.
- Potential Sciences is developing an AI model based on the fundamental laws of physics rather than relying primarily on historical experimental data.
- The company’s approach could make AI calculations for chemical design up to 100 times cheaper than existing methods, according to the UK Government announcement.
- The technology could help researchers investigate new treatments for diseases including cancer and Parkinson’s.
- The funding package includes investment and access to advanced computing infrastructure through the UK’s AI Research Resource.
- The Isambard-AI supercomputer in Bristol is among the computing resources being made available to the company.
- Investors participating in the funding round include Twin Path Ventures, Odyssey, Portfolio Ventures, Blue Wire Capital, rule30, Nauta Capital and Lightfield Equity.
- Stripe co-founder Patrick Collison and Chris Gibson, co-founder and former chief executive of Recursion, are among the angel investors.
- AI engineer Andrew Fitzgibbon and entrepreneur James Hawkins will support Potential Sciences as advisers.
- AI Minister Kanishka Narayan, Science Minister Chris McDonald, Lord Vallance and Sovereign AI Investment Partner Joséphine Kant highlighted the company’s scientific and commercial potential.
- The announcement follows the Chancellor’s confirmation of an additional £140 million in backing for Sovereign AI, including £60 million for investments and £80 million for its R&D Procurement Scheme.
- Sovereign AI is also expanding its investment priorities into Physical and Industrial AI, including robotics, autonomous systems and advanced manufacturing.
The UK Government’s Sovereign AI venture fund has backed British startup Potential Sciences through an eight-figure funding round, combining financial investment with access to advanced national computing infrastructure to accelerate the use of artificial intelligence in chemical research and drug discovery. Announced on Thursday, 5 November 2026, the backing is intended to help the company develop technology that uses the fundamental laws of physics to improve chemical modelling, potentially making the calculations required for designing new chemicals up to 100 times cheaper than existing approaches. The initiative reflects the Government’s ambition to strengthen Britain’s domestic AI industry, support high-potential technology businesses and accelerate scientific innovation with potential applications in the development of new medicines.
What Is Potential Sciences Developing to Change AI-Powered Chemistry?
Potential Sciences is pursuing a different approach to applying artificial intelligence to chemistry, particularly in the discovery and development of new medicines. Rather than depending primarily on existing experimental records, the company is developing an AI model that focuses on the fundamental laws of physics to calculate and predict how chemical systems behave.
The distinction is important because conventional approaches to AI-assisted drug discovery frequently depend on large quantities of experimental data. Producing this information can require extensive laboratory work, specialist equipment, significant financial resources and considerable time. These requirements can restrict the number of chemical compounds researchers can investigate and slow the development of new scientific applications.
According to the UK Government’s announcement, the availability of reliable experimental data has become a significant obstacle to further progress in AI-driven chemical discovery. Although AI has created opportunities to accelerate research, its effectiveness can be limited when the underlying information is expensive and difficult to obtain.
Potential Sciences aims to address this challenge by incorporating fundamental physical principles into its computational approach. This could allow its technology to generate useful chemical calculations without relying exclusively on the historical experimental record.
The company believes that this approach could make the calculations required for chemical design up to 100 times cheaper than existing methods. If achieved in practice, the improvement could significantly expand the range of chemical problems researchers can investigate.
The announcement also highlights the relationship between Artificial Intelligence (AI) and scientific computing. As increasingly sophisticated models become available, the ability to process complex scientific information efficiently is becoming an important consideration for researchers and technology businesses.
The company’s approach is particularly relevant to drug discovery, where researchers need to understand molecular interactions and identify promising chemical structures before potential medicines can progress through further development and testing.
However, the proposed cost reduction remains a potential capability described in the Government’s announcement rather than evidence that new treatments have already been developed or approved.
Why Could the Technology Help Accelerate Drug Discovery?
Drug discovery is a complex process involving the identification, design, and evaluation of potential compounds that could eventually become medicines. Researchers must investigate how chemical structures behave, assess their properties, and establish whether promising candidates warrant further development.
Traditional research methods can be expensive and time-consuming, particularly when extensive laboratory experiments are required to produce the information needed by computational models.
Potential Sciences is attempting to reduce some of these limitations by using physics-based calculations to support AI-driven chemical design.
The UK Government identified cancer and Parkinson’s disease as examples of conditions for which advances in chemical discovery could create new research opportunities. The announcement explained that more affordable computational methods could allow scientists to investigate diseases and potential treatments that have previously received less attention because of their research costs.
This is particularly relevant to rare diseases and other conditions for which developing new treatments may be commercially or scientifically challenging.
AI Minister Kanishka Narayan highlighted this opportunity in his statement accompanying the announcement.
Narayan said:
“Solving chemistry’s ‘data bottleneck’ could allow researchers to explore new treatments for diseases that are currently deemed too rare or expensive to focus on.”
He also described the company’s work as an example of AI pushing the boundaries of innovation, with the ultimate objective of improving people’s lives.
The potential applications extend beyond identifying new medicines. More efficient chemical calculations could also support research into materials, molecular structures and other scientific applications where understanding the behaviour of chemical systems is important.
Nevertheless, computational improvements alone cannot establish whether a potential medicine will be safe or effective. Any prospective treatment would still need to undergo appropriate scientific validation, preclinical research and clinical assessment before it could be considered for medical use.
How Does Potential Sciences’ Quantum Chemistry Approach Work?
A central element of Potential Sciences’ development strategy is its work on quantum chemistry and graphics processing units (GPUs).
Quantum chemistry applies principles of quantum mechanics to understand and calculate the behaviour of atoms, electrons, and molecules. These calculations can provide detailed information about chemical structures and interactions, making them valuable for scientific research and the development of new compounds.
However, achieving high levels of computational accuracy can require substantial processing resources. This can make advanced calculations expensive, particularly when researchers need to perform them repeatedly across large numbers of possible chemical structures.
Potential Sciences is seeking to address this limitation by adapting quantum chemistry software to operate more efficiently on modern GPU hardware.
In his statement, Hatem Helal, founder and chief executive of Potential Sciences, explained the reasoning behind the company’s approach.
Helal said:
“AI for drug discovery has learned almost everything the existing experimental record can teach it. The next leap needs new data, and the laws of physics can supply it, as long as your software can use modern hardware.”
He also explained that the company had rebuilt quantum chemistry for GPUs to make high-accuracy calculations affordable at the scale required by AI systems.
Helal added:
“We rebuilt quantum chemistry for GPUs so that gold-standard accuracy is affordable at the scale AI needs.”
He further indicated that the company’s efficiency improvements could substantially reduce the computing infrastructure needed to perform complex scientific calculations.
The founder’s comments illustrate the company’s intention to address both the scientific and infrastructure challenges associated with AI-powered chemistry.
Rather than treating access to experimental data and computing capacity as separate issues, Potential Sciences is attempting to combine physics-based modelling with more efficient hardware utilisation.
If the approach delivers the expected performance, it could allow researchers and AI developers to investigate a broader range of chemical problems without requiring the same level of financial and computing resources associated with conventional approaches.
How Will Sovereign AI Support the Company’s Development?
The UK Government’s support for Potential Sciences combines financial investment with access to advanced computing infrastructure.
According to the Government’s announcement, Sovereign AI is participating as an investor in the company’s eight-figure funding round.
The financial investment is intended to support the startup as it develops its technology and expands its operations. However, the Government has not disclosed the precise amount being invested in Potential Sciences.
The support also includes access to computing resources through the AI Research Resource (AIRR), the UK’s national network of advanced supercomputers.
This infrastructure is particularly relevant to Potential Sciences because its work involves computationally intensive chemical modelling and AI development.
Training and operating advanced AI models require substantial processing capacity. For a scientific startup, obtaining sufficient access to specialist hardware can represent a considerable financial and operational challenge.
By providing access to national computing infrastructure, Sovereign AI aims to reduce this barrier and help the company advance its research without having to independently finance all the necessary computing resources.
The support includes access to the Isambard-AI supercomputer in Bristol, which forms part of the UK’s advanced computing infrastructure.
This arrangement also demonstrates how government-backed investment programmes can support technology companies through resources beyond traditional financial funding.
For Potential Sciences, the combination of investment and computing capacity could help it develop and test its technology while pursuing further commercial opportunities.
Who Is Investing in Potential Sciences’ Funding Round?
Sovereign AI is not the only investor participating in the funding round.
The UK Government announcement identified several other financial backers, demonstrating interest from a combination of venture capital firms and individual investors.
The named institutional and venture investors include:
- Twin Path Ventures
- Odyssey
- Portfolio Ventures
- Blue Wire Capital
- rule30
- Nauta Capital
- Lightfield Equity
The funding round also includes angel investment from Patrick Collison, co-founder of Stripe, and Chris Gibson, co-founder and former chief executive of Recursion.
Their participation brings experience from the technology and biotechnology sectors into the company’s investor group.
The announcement also identified two individuals who will support Potential Sciences in advisory roles: AI engineer Andrew Fitzgibbon and entrepreneur James Hawkins.
Their involvement is intended to provide additional expertise as the company develops its technology and pursues its business ambitions.
The Government has confirmed that the funding round is in the eight-figure range but has not provided an exact valuation or individual investment breakdown.
In its editorial notes, the Government explained that Sovereign AI typically makes equity investments of approximately £1 million to £10 million, although the amount varies depending on the circumstances of each company.
It also stated that the fund does not generally disclose specific investment figures because of commercial sensitivities.
Consequently, the precise financial contribution made by Sovereign AI and the other investors to this particular round remains undisclosed.
What Did UK Government Ministers Say About the Investment?
The announcement attracted comments from senior Government representatives and individuals involved in the country’s AI investment strategy.
AI Minister Kanishka Narayan described Potential Sciences as a company pursuing an opportunity that builds on Britain’s expertise in data, fundamental science and computing.
Narayan said:
“Potential Sciences is a startup that’s grasping an opportunity Britain is uniquely well-placed to capitalise on.”
He emphasised that combining these areas of expertise could help unlock new opportunities in medical research. He also highlighted the possibility of investigating treatments for diseases that have traditionally been considered too rare or expensive to attract sufficient research investment.
Science Minister Chris McDonald also welcomed the investment, drawing on his professional background as a chemical engineer.
McDonald said:
“As a former chemical engineer, I know firsthand how the field can make a real difference; whether that’s discovering new medicines to treat and beat disease, or finding cheaper and more efficient ways to bring innovations to life.”
He described the investment as an example of British innovation and the opportunities created by bringing scientific research together with AI.
McDonald added that supporting domestic technology businesses such as Potential Sciences could help companies realise their ambitions while strengthening the UK’s scientific and innovation capabilities.
His comments also highlighted the wider economic and research benefits that could emerge from investment in homegrown technology businesses.
Chair of the Prime Minister’s AI Taskforce, Lord Vallance, also commented on the company’s proposed approach.
Vallance said:
“Drug discovery is an expensive and uncertain business, and we still don’t have effective treatments and cures for many diseases.”
He described Potential Sciences’ approach, which combines quantum science and AI, as a potentially significant development.
According to Vallance, the company’s proposed solution reflects the type of scientific ambition and innovation that Sovereign AI intends to encourage through its investment activities.
Sovereign AI Investment Partner Joséphine Kant also shared her assessment of the company’s founder and its long-term ambitions.
Kant explained that she first met Hatem Helal in Cambridge and was impressed by his technical knowledge, ambition and approach to building a team.
She said:
“He combines technical excellence with low ego and unapologetic ambition.”
Kant also highlighted Helal’s willingness to bring in people with expertise in areas beyond his own specialism.
She described Potential Sciences as having the ambition to become a frontier laboratory for chemistry, with the potential to change how the field operates.
These statements reflect the Government’s confidence in the company’s technical direction, although its longer-term scientific and commercial achievements will depend on the results of its research and development.
What Is Sovereign AI and Why Is It Investing in British Startups?
Sovereign AI is a UK Government-backed investment initiative designed to help promising domestic AI companies develop, secure resources and compete internationally.
Its approach combines elements of venture capital investment with access to Government-supported infrastructure and other forms of assistance.
Rather than concentrating exclusively on established technology businesses, the fund also targets early-stage and growth-stage companies with the potential to develop strategically important AI capabilities in Britain.
The Government’s wider objective is to strengthen the UK’s position in the international AI industry by helping domestic companies retain their research capabilities, talent and business operations within the country.
The initiative was introduced as a £500 million commitment to support British AI businesses.
In its announcement published on 16 April 2026, the Government explained that the fund would provide a combination of investment, access to supercomputers, research and development support and assistance with attracting international talent.
The initial programme also included support for companies requiring specialist computing resources to develop advanced AI models.
The earlier announcement identified Callosum as the fund’s first equity investment, while six other startups were selected to receive access to the AI Research Resource.
Those companies included Prima Mente, Cosine, Cursive, Doubleword, Twig Bio and Odyssey.
The programme was designed to address a major challenge facing AI startups: the considerable cost of obtaining the hardware and infrastructure required to train and operate advanced models.
Potential Sciences’ latest funding round represents a further application of this investment strategy, particularly in scientific research and AI-driven drug discovery.
How Does the Latest Announcement Relate to the Government’s £140 Million Commitment?
The Potential Sciences investment announcement follows a further financial commitment to Sovereign AI confirmed by the Chancellor in the Budget approximately one week earlier.
According to the Government, the additional support totals £140 million and is divided between two areas.
The first allocation comprises £60 million to support the fund’s investments, providing additional resources for backing promising AI companies.
The remaining £80 million is allocated to Sovereign AI’s Research and Development Procurement Scheme, which is intended to support research and development activities associated with the programme.
The Budget announcement also confirmed that Sovereign AI would expand its investment priorities to include Physical and Industrial AI.
This represents a broader approach to supporting AI applications beyond software and digital services.
Physical and Industrial AI includes technologies such as robotics, autonomous systems and advanced manufacturing. These areas combine AI capabilities with physical equipment, industrial processes and automated operations.
The expansion builds on the UK’s existing research base and its developing strengths in advanced technology.
For Potential Sciences, the funding announcement is particularly relevant because its work connects AI development with scientific computing and physical principles.
Although the company operates in a different field from industrial robotics and manufacturing automation, its technology demonstrates the potential for AI to support research and innovation across specialised technical disciplines.
The additional financial commitment also indicates that the Government intends to continue supporting domestic AI businesses as the programme develops.
What Role Will the UK Supercomputing Infrastructure Play?
Access to advanced computing infrastructure is a significant part of the support package announced for Potential Sciences.
The AI Research Resource provides access to the UK’s national network of advanced supercomputers, helping researchers and businesses undertake computational work that would otherwise require substantial investment in specialist hardware.
For Potential Sciences, this infrastructure could be particularly important when developing and testing its quantum chemistry models.
GPU-based computing allows suitable workloads to be distributed across specialised processing hardware, improving the efficiency of complex calculations.
However, the availability of computing resources does not automatically guarantee that an AI model will deliver the expected scientific results. The quality of its underlying methods, accuracy, performance and practical usefulness will remain important measures of success.
The inclusion of Isambard-AI in Bristol is notable because it gives the company access to a major national computing resource without having to rely entirely on privately owned infrastructure.
The arrangement also supports the Government’s wider ambition to make advanced computing capacity available to British research and technology businesses.
By combining access to supercomputers with financial investment, Sovereign AI is attempting to address two important requirements for developing advanced AI businesses: funding and computational capacity.
This could be particularly relevant to startups operating in scientific fields where complex simulations and calculations require significant processing resources.
What Does the Investment Mean for Britain’s AI and Life Sciences Industries?
The backing for Potential Sciences illustrates how AI investment is increasingly extending into specialist scientific and industrial applications.
While much public attention surrounding artificial intelligence focuses on generative AI, digital assistants and software development, the technology is also being applied to areas such as chemistry, biotechnology, materials research and pharmaceutical development.
AI-driven scientific discovery could create opportunities for businesses capable of combining specialised research expertise with advanced computing systems.
For Britain, supporting these companies also has potential implications for its wider life sciences and technology industries.
The UK has an established scientific research base, universities, biotechnology businesses and technology investment networks. Government support for companies working across these areas could help translate research capabilities into commercially viable products and services.
Potential Sciences’ approach also highlights the importance of computational efficiency.
If the company can demonstrate that its technology produces accurate chemical calculations at substantially lower costs, it could make certain types of research more accessible.
This may allow researchers to investigate scientific questions that currently receive limited attention because of the financial and computational resources required.
However, the commercial significance of the technology will depend on whether the proposed improvements can be demonstrated consistently and whether pharmaceutical and scientific organisations find the resulting tools useful.
The Government’s broader investment strategy also seeks to ensure that companies receiving support maintain meaningful operations and employment in Britain.
According to the announcement, Sovereign AI-backed startups have a substantial UK presence through their founders, leadership teams, operational headquarters or a significant proportion of their workforce.
The Government said these businesses contribute to well-paid employment across the country, supporting its ambition to generate economic growth in different regions.
Potential Sciences therefore forms part of a wider effort to connect technological development with domestic business growth and employment.
What Happens Next for Potential Sciences?
The immediate priority for Potential Sciences will be to use its investment and computing support to advance its technology.
The eight-figure funding round provides financial backing, while access to the AI Research Resource gives the company an additional route to the computing capacity needed for its research.
The company’s longer-term progress will depend on several factors, including its ability to improve computational performance, demonstrate the accuracy of its quantum chemistry models, and establish practical applications for its technology.
Its ambitions also extend beyond developing an individual AI model. Sovereign AI Investment Partner Joséphine Kant’s comments indicate that the company aims to become a frontier laboratory for chemistry, potentially developing a broader scientific capability.
For the pharmaceutical and biotechnology sectors, the key question will be whether the technology can translate its proposed computational advantages into useful improvements in chemical research and drug discovery.
The announcement does not establish that Potential Sciences has already produced new medicines or demonstrated clinical benefits. Instead, it outlines the company’s technical approach, funding support and potential contribution to future scientific research.
Nevertheless, the backing represents a significant development for a British startup working at the intersection of AI, quantum chemistry and scientific computing.
As the UK Government continues to support domestic AI businesses, developments such as this highlight the growing importance of Artificial Intelligence (AI) and Data Science and Visualization in enabling scientific research, processing complex information and developing new computational methods.
For organisations operating in advanced technology and research-intensive industries, the ability to understand AI systems, computational modelling, and scientific data is becoming increasingly relevant to innovation and business development.